{
    "clinical_study": {
        "@rank": "122873", 
        "arm_group": [
            {
                "arm_group_label": "MK-8228", 
                "arm_group_type": "Experimental", 
                "description": "MK-8228 oral or intravenous (IV) formulation will be administered once daily for 14 weeks after transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo oral or IV formulation will be administered once daily for 14 weeks after transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the efficacy and safety of MK-8228 for the prevention of\n      clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic\n      hematopoietic stem cell transplant. The hypothesis being tested is that MK-8228 is superior\n      to placebo in the prevention of clinically-significant CMV infection through 24 weeks after\n      transplant."
        }, 
        "brief_title": "MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Cytomegalovirus Infections", 
        "condition_browse": {
            "mesh_term": "Cytomegalovirus Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has documented seropositivity for CMV within 1 year before hematopoietic stem cell\n             transplant (HSCT)\n\n          -  Receiving first allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord\n             blood transplant)\n\n          -  Female or male participant who is not of reproductive potential, or, if of\n             reproductive potential, agrees to true abstinence or to use (or have their partner\n             use) 2 acceptable methods of birth control from the time of consent through 90 days\n             after the last dose of study drug\n\n          -  Able to read, understand, and complete questionnaires and diaries\n\n        Exclusion Criteria:\n\n          -  Received a previous allogeneic HSCT (previous autologous HSCT is acceptable)\n\n          -  History of CMV end-organ disease within 6 months before randomization\n\n          -  Has evidence of CMV viremia from a central or local laboratory at any time before\n             randomization\n\n          -  Received the following within 7 days before screening or plans to receive during the\n             study: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, or\n             famciclovir\n\n          -  Received the following within 30 days before screening or plan to receive during the\n             study: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent\n             or biological therapy\n\n          -  Has suspected or known hypersensitivity to ingredients of MK-8228 (letermovir)\n             formulations\n\n          -  Has severe hepatic insufficiency within 5 days before randomization\n\n          -  Has end-stage renal impairment\n\n          -  Has an uncontrolled infection on the day of randomization\n\n          -  Requires mechanical ventilation or is hemodynamically unstable at the time of\n             randomization\n\n          -  Has documented positive results for human immunodeficiency virus (HIV) antibody,\n             hepatitis C virus (HCV) antibody with detectable HCV ribonucleic acid, or hepatitis B\n             surface antigen (HBsAg) within 90 days before randomization\n\n          -  Has active solid tumor malignancies with the exception of localized basal cell or\n             squamous cell skin cancer or the condition under treatment (for example, lymphoma)\n\n          -  Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from\n             the time of consent through 90 days after the last dose of study drug\n\n          -  Is expecting to donate eggs or sperm from the time of consent through 90 days after\n             the last dose of study drug\n\n          -  Has participated in a study with an unapproved investigational compound (monoclonal\n             antibodies are excepted) or device within 28 days of the first dose of study drug\n\n          -  Has previously participated in a MK-8228 (letermovir) study\n\n          -  Has, is, or is planning (during the study) to participate in any study involving\n             administration of a CMV vaccine or another CMV investigational agent\n\n          -  Is a user of recreational or illicit drugs or has a recent history (<=1 year) of drug\n             or alcohol abuse or dependence"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "540", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137772", 
            "org_study_id": "8228-001", 
            "secondary_id": "2013-003831-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-8228", 
                "intervention_name": "MK-8228", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants with Clinically-Significant CMV Infection", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks after transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137772"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to Onset of Clinically-Significant CMV Infection", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks after transplant"
            }, 
            {
                "measure": "Percentage of Participants with Clinically-Significant CMV Infection", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks after transplant"
            }, 
            {
                "measure": "Percentage of Participants with CMV Disease", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks after transplant"
            }, 
            {
                "measure": "Percentage of Participants with CMV Disease", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks after transplant"
            }, 
            {
                "measure": "Percentage of Participants with Pre-emptive Therapy for CMV Viremia", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks after transplant"
            }, 
            {
                "measure": "Percentage of Participants with Pre-emptive Therapy for CMV Viremia", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks after transplant"
            }, 
            {
                "measure": "Time to Initiation of Pre-emptive Therapy for CMV Viremia", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks after transplant"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}